Tech Company Financing Transactions

InCarda Therapeutics Funding Round

InCarda Therapeutics, based in Newark, scored $30 million from Innoviva, Deerfield Capital and Healthcap Venture Capital.

Transaction Overview

Company Name
InCarda Therapeutics
Announced On
10/22/2020
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors

Innoviva (Lead Investor)

Deerfield Capital

Healthcap Venture Capital (John Christenson)

Morningside Group (Reenie McCarthy)

Proceeds Purpose
Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm (flecainide for inhalation), the company's lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
39899 Balentine Dr. 185
Newark, CA 94560
USA
Phone
Undisclosed
Website
www.incardatherapeutics.com
Email Address
[email protected]
Overview
Incarda Therapeutics develops treatments for cardiovascular diseases.
Profile
InCarda Therapeutics LinkedIn Company Profile
Social Media
InCarda Therapeutics Company Twitter Account
Company News
InCarda Therapeutics News
Facebook
InCarda Therapeutics on Facebook
YouTube
InCarda Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Grace Colón
  Grace Colón LinkedIn Profile  Grace Colón Twitter Account  Grace Colón News  Grace Colón on Facebook
Chief Financial Officer
Guy Anthony
  Guy Anthony LinkedIn Profile  Guy Anthony Twitter Account  Guy Anthony News  Guy Anthony on Facebook
Chief Medical Officer
Luiz Belardinelli
  Luiz Belardinelli LinkedIn Profile  Luiz Belardinelli Twitter Account  Luiz Belardinelli News  Luiz Belardinelli on Facebook
Chief Operating Officer
Carlos Schuler
  Carlos Schuler LinkedIn Profile  Carlos Schuler Twitter Account  Carlos Schuler News  Carlos Schuler on Facebook
Controller
Leo Santana
  Leo Santana LinkedIn Profile  Leo Santana Twitter Account  Leo Santana News  Leo Santana on Facebook
Vice President
Debra Echt
  Debra Echt LinkedIn Profile  Debra Echt Twitter Account  Debra Echt News  Debra Echt on Facebook
VP - Bus. Development
Jeffrey Ho
  Jeffrey Ho LinkedIn Profile  Jeffrey Ho Twitter Account  Jeffrey Ho News  Jeffrey Ho on Facebook
VP - Human Resources
Anna Popovici
  Anna Popovici LinkedIn Profile  Anna Popovici Twitter Account  Anna Popovici News  Anna Popovici on Facebook
VP - Operations
Meisa Propst
  Meisa Propst LinkedIn Profile  Meisa Propst Twitter Account  Meisa Propst News  Meisa Propst on Facebook
VP - Product Management
Mick Hurrey
  Mick Hurrey LinkedIn Profile  Mick Hurrey Twitter Account  Mick Hurrey News  Mick Hurrey on Facebook
VP - R & D
Prashanti Madhavapeddi
  Prashanti Madhavapeddi LinkedIn Profile  Prashanti Madhavapeddi Twitter Account  Prashanti Madhavapeddi News  Prashanti Madhavapeddi on Facebook
VP - Regulatory Affairs
Margaret Dillon
  Margaret Dillon LinkedIn Profile  Margaret Dillon Twitter Account  Margaret Dillon News  Margaret Dillon on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/22/2020: Immerse venture capital transaction
Next: 10/22/2020: Bind Benefits venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.